Organization · Venture Capital
SR One Capital Management
SR One Capital Management is a biotechnology venture capital firm based in Redwood City, California, and London, specializing in early-stage investments in life sciences companies. The firm employs a 'back-and-build' approach to support innovative therapeutics development.
Overview
What SR One Capital Management does
What SR One Capital Management is
SR One Capital Management is a biotechnology venture capital firm based in Redwood City, California, and London, specializing in early-stage investments in life sciences companies. The firm employs a 'back-and-build' approach to support innovative therapeutics development.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 1985
- Approximate age
- About 41 years
- Structured capabilities
- Funder
- Last reviewed
- April 28, 2026
Official channels
Find SR One Capital Management elsewhere
Open the official website or a supported primary organization account.
Capability profile
SR One Capital Management as a funder
Investment thesis
SR One Capital Management partners with founders to translate innovative science into medicines, focusing on companies with strong fundamentals and defined development pathways in biotechnology.
Focus narrative
SR One invests in biotechnology companies across various sectors, including cardiometabolic, CNS, immunology, infectious disease, oncology, rare diseases, renal, and neuropsychiatry. The firm employs a back-and-build investment strategy, targeting companies at different stages of development, from clinical to preclinical.
Value beyond capital
SR One adds value to its portfolio companies by providing capital, company-building support, and access to scientific and operational networks. The firm's transatlantic model enhances opportunities for collaboration and innovation in biotechnology.
Focus and fit
- Stages
- Seed · Series A · Series B · Growth Equity
- Regions
- North AmericaEurope
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded notable exits
- CRISPR Therapeutics and Arcellx
Portfolio context
AirNexis Therapeutics, Inc.: Developing therapeutics for pulmonary diseases. Innovative gene-based immuno-oncology treatments: Focused on solid tumors. Clinical-stage companies developing therapies for viral diseases, autoimmune diseases, and oncology. Transformative gene-based medicines for serious human diseases. Clinical-stage biopharmaceutical company dedicated to improving treatments for gout. Advanced inhaled anti-infectives for life-threatening lung infections. Clinical-stage company focused on orphan renal diseases.
Common questions
What to know about SR One Capital Management
Upseed classifies SR One Capital Management under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 28, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.